Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
Felix BehlingAlonso Barrantes-FreerMarco SkardellyMaike NieserArne ChristiansFlorian StockhammerVeit RohdeMarcos TatagibaChristian HartmannChristine StadelmannJens SchittenhelmPublished in: Diagnostic pathology (2016)
Our data suggest routine screening for BRAF V600E mutations for glioblastomas WHO grade IV below the age of 30, especially in glioblastomas with epithelioid features and in all rhabdoid meningiomas WHO grade III. For colorectal carcinoma, thyroid cancer, malignant melanoma and gliomas BRAF V600E immunostaining is sufficient for screening purposes. We also recommend routine immunohistochemical staining followed by sequencing validation in rare CNS metastases or metastases of unknown primary. Immunohistochemical analysis using mutation-specific antibodies on tissue microarrays is a feasible, time- and cost-efficient approach to high-throughput screening for specific mutations in large tumor series but sequencing validation is necessary in unexpected cases.